Karvedilol

Quick links to important sections

Medically reviewed

Marina Burgos

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Karvedilol

Property Description
Active Ingredient Carvedilol (INN)
Form Tablet, extended-release capsule
Pharmacological Class Alpha and beta adrenergic antagonist (α/β blocker)
Origin Synthetic
Route of Administration Oral

What Type of Drug is Carvedilol? (Classification and Identity)

Carvedilol is a highly specialized, synthetic, prescription-only medication primarily classified as an alpha and beta adrenergic antagonist (α/β blocker), placing it within the group of antihypertensive and cardiovascular drugs. This dual-action classification signifies the agent blocks the effects of catecholamines at both alpha-1 and beta receptors in the body, a distinction that is clinically recognized for providing comprehensive cardiovascular support.

The core chemical entity is the single-ingredient product, Carvedilol (INN), which is formulated as a racemic mixture of S(-) and R(+) enantiomers. This composition is necessary for the drug’s distinct profile. Carvedilol is a compound providing combined alpha-1- and beta-adrenergic receptor-blocking activity.

Composition and Physical Form of Carvedilol

The active ingredient is Carvedilol, a compound prepared for oral administration in two main dosage form(s): a conventional release tablet and an extended-release capsule. The medication is manufactured with standard pharmaceutical excipients necessary to stabilize these solid oral forms. A key factor is the availability of the extended-release capsule, which is designed to maintain consistent levels of the active compound over a longer duration.

What is the General Purpose of Carvedilol’s Dual Action?

The overall general purpose of Carvedilol’s dual action is to promote more efficient function within the circulatory system by concurrently regulating the heart's activity and reducing arterial pressure. This is achieved through the mechanism principles of controlled slowing of the heart rate and inducing peripheral vasodilating effects. The combined effect of these actions lessens the overall resistance against which the heart pumps, thereby supporting consistent and optimized cardiac performance in patients.

What side effects are possible with Karvedilol?

Possible Side Effects and Safety Information

Common Adverse Reactions

Regulatory documents classify the most frequent adverse reactions associated with Karvedilol use, particularly in patients treated for heart failure and post-myocardial infarction left ventricular dysfunction, as occurring in at least 10% of patients. These common side effects primarily include dizziness, fatigue, hypotension (low blood pressure), bradycardia (slow heart rate), diarrhea, hyperglycemia, and unexplained weight increase.

Serious and Clinically Significant Adverse Reactions

The most significant safety concerns include worsening heart failure or fluid retention, especially during the initial phase of treatment or dose increases, and severe bradycardia which may necessitate a dose reduction. Syncope (fainting) and marked hypotension are also documented as serious adverse reactions. Abrupt cessation of therapy is strictly advised against due to the risk of precipitating an acute exacerbation of coronary artery disease, potentially leading to myocardial infarction or severe chest pain.

Safety Restrictions and Population Considerations

Karvedilol is formally contraindicated in patients with conditions such as bronchial asthma or related bronchospastic diseases, second- or third-degree atrioventricular (AV) block, sick sinus syndrome (unless a permanent pacemaker is present), cardiogenic shock, and severe hepatic impairment.

In patients with diabetes, Karvedilol may mask the typical warning signs of hypoglycemia, such as a fast heartbeat, and may worsen blood glucose control. Close blood glucose monitoring is noted as necessary for this patient group. Caution is also advised in patients with peripheral vascular disease due to the potential for aggravating symptoms of arterial insufficiency.

Overdose and Emergency Response

Overdose: When to Seek Immediate Medical Help

Karvedilol overdose is a serious medical emergency and requires prompt, professional attention. The most severe health risks stem from the excessive blocking of receptors, which critically affects the heart and circulatory system.

Immediately call emergency medical services or a poison control center if you suspect an overdose. Do so without delay if the person has collapsed, has difficulty breathing, is unconscious, or is experiencing a seizure.


Key Symptoms and Manifestations

Taking too much carvedilol can lead to life-threatening symptoms, including:

System Documented Overdose Symptoms
Cardiovascular Severe hypotension (low blood pressure), profound bradycardia (very slow heart rate), cardiac insufficiency, cardiogenic shock, and cardiac arrest (heart stopping).
Respiratory Bronchospasm (severe breathing difficulty, wheezing).
CNS/Systemic Dizziness, fainting (syncope), weakness, vomiting, loss of consciousness, seizures (convulsions), and bluish-colored skin or nails (cyanosis).

Emergency Actions

The management of a carvedilol overdose is supportive, aiming to counteract the excessive effects of the drug. Treatment may include specific medications to raise the heart rate and blood pressure, such as atropine or glucagon. Patients require continuous monitoring in a hospital setting to stabilize vital functions and manage the severe effects on the cardiovascular system.

Therapeutic Uses of Karvedilol

Karvedilol: Main Uses and Benefits

Karvedilol is a prescribed medication intended for the management of specific cardiovascular conditions. The primary therapeutic domains for this drug include the treatment of high blood pressure, known as hypertension.

It is also used to address chronic heart failure of mild to severe presentation. In this context, Karvedilol is typically utilized alongside other appropriate medications to support heart function and may reduce the risk of hospitalization associated with this condition. The treatment is part of a complete management plan.

Additionally, Karvedilol is indicated to support heart function following a myocardial infarction (heart attack) in clinically stable patients who have been diagnosed with left ventricular dysfunction. Use in this setting may help stabilize cardiovascular outcomes.

It is essential to take this medication exactly as directed by a healthcare professional as part of a tailored regimen.


Quick Facts (Therapeutic Domains)

  • Chronic Heart Failure: Helps manage mild-to-severe forms of this condition.
  • High Blood Pressure (Hypertension): Used for the management of essential hypertension.
  • Post-Myocardial Infarction: Addresses left ventricular dysfunction after a heart attack.

Eligibility and Restrictions for Use

Carvedilol eligibility for use is defined by specific population criteria and patient conditions outlined in official regulatory documents.

Populations for Whom Use is Contraindicated

The medicine must not be used in patients with the following conditions, as they are designated as absolute prohibitions:

Contraindicated Condition
Severe Hepatic Impairment or clinically manifest liver dysfunction
Cardiogenic Shock or decompensated heart failure requiring IV inotropic therapy
Bronchial Asthma or related bronchospastic conditions
Second- or Third-Degree AV Block, Sick Sinus Syndrome, or Severe Bradycardia (unless a permanent pacemaker is in place)
History of serious hypersensitivity reaction to Carvedilol or any component

Age- and Condition-Based Restrictions

Restricted Population
Pediatric Patients: Safety and effectiveness have not been established in children or adolescents under 18 years.
Pregnancy/Lactation: Use during pregnancy is generally considered only if potential benefit justifies the risk; official labeling recommends against breastfeeding.
Type 2 Diabetes: Use requires caution due to the potential to mask signs of hypoglycemia and requires careful blood glucose monitoring.
Non-Allergic Bronchospasm: Use should generally be avoided; if necessary, it is restricted to the lowest effective dose with caution.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Official regulatory documents define the interaction profile of Karvedilol based on pharmacokinetic and pharmacodynamic constraints. Co-administration with strong metabolic inhibitors or inducers may significantly alter the drug's systemic exposure. For instance, CYP2D6 inhibitors (e.g., Fluoxetine, Amiodarone) may increase Karvedilol plasma concentrations, while the strong CYP Inducer Rifampin is documented to cause a reduction in exposure by approximately 70%.

Karvedilol's effect as a P-glycoprotein inhibitor is also documented, which can lead to increased trough concentrations of co-administered substrates, such as Cyclosporine.

Pharmacodynamic interactions primarily involve additive effects on the cardiovascular system. Combining Karvedilol with certain Calcium Channel Blockers (Verapamil or Diltiazem type) increases the risk of AV conduction disorders. Similarly, co-administering with Digitalis Glycosides increases the risk of bradycardia. Concomitant use with Insulin or Oral Hypoglycemics may enhance the blood-sugar-reducing effect and can mask the symptoms of hypoglycemia.

Regarding substances, patients with heart failure are required to take the medication with food to slow absorption and reduce orthostatic effects. Use with alcohol may potentiate the hypotensive effects. A specific interaction-related constraint is the official contraindication in patients with severe hepatic impairment, where impaired metabolism causes Karvedilol plasma levels to be highly elevated.

Mechanism of Action

Blockade of Adrenergic Receptors (beta and alpha1)

Karvedilol functions as a non-selective adrenergic receptor antagonist by binding to and blocking beta1, beta2, and alpha1 receptors. This action prevents the binding of endogenous catecholamines, such as norepinephrine and epinephrine, thereby disrupting sympathetic nervous system signaling at target tissues. The beta1 antagonism reduces cyclic AMP (cAMP) signaling within myocardial cells, which decreases the force of heart muscle contraction (inotropy) and heart rate (chronotropy). Simultaneously, the alpha1 antagonism prevents smooth muscle contraction in peripheral vasculature, inducing blood vessel widening (vasodilation). The result is a decrease in systemic vascular resistance and a reduction in myocardial oxygen demand.

Modulation of Oxidative Stress

Independent of its receptor blockade, Karvedilol engages in a secondary mechanism by functioning as a direct chemical antioxidant. This property involves the scavenging and neutralizing of reactive oxygen species (free radicals). By modulating oxidative stress, the mechanism contributes to the maintenance of structural integrity in myocardial cells and vascular tissue through direct chemical interaction.

Dosage and Administration Information

Official Administration Guidelines for Karvedilol

Karvedilol is administered exclusively via the oral route, available as both a conventional release tablet and an extended-release capsule. The key usage principle involves a structured, slow titration of the dosage over time.

Dosing and Frequency Patterns

The conventional tablet is generally taken twice daily (BID), while the extended-release capsule is taken once daily (QD). Therapy always begins at the lowest labeled dose, with increases occurring gradually. For Chronic Heart Failure, the starting dose is 3.125 mg twice daily, and the dose is only doubled after a period of at least two weeks to ensure tolerance. For managing Hypertension, the starting dose is typically 6.25 mg twice daily, with subsequent adjustments occurring generally no more frequently than every 7 to 14 days.

Administration Instructions

Conventional release tablets must be taken with food to modulate absorption. Extended-release capsules should be swallowed whole and must not be crushed or chewed, though the beads may be sprinkled onto a small amount of soft, cool food and ingested immediately.

Karvedilol is intended for long-term management and should never be stopped abruptly. If discontinuation is necessary, the protocol requires the dose to be gradually reduced over one to two weeks. If a dose is missed, patients should omit the missed dose and take the next dose at the regular time; doubling a dose is not advised.

Recent Clinical Evidence

Research Evidence / Overview of studies for Karvedilol

The information presented here describes the structure of clinical research that has evaluated Carvedilol.


Evidence for use in Chronic Heart Failure (CHF)

Research exploring outcomes related to severe, moderate, and mild chronic heart failure is primarily based on large-scale Randomized Controlled Trials (RCTs). The main outcomes that researchers monitored included survival (all-cause mortality) and the frequency of hospitalization for cardiovascular events. Studies also monitored physiological strain, specifically assessing the heart's pumping ability, often measured as the Left Ventricular Ejection Fraction (LVEF). Studies reported measurements that demonstrated patterns related to all-cause mortality and hospitalization frequency between the study groups over the observation periods. Evidence remains limited and inconsistent regarding some indirect measures, such as whether changes were observed in exercise tolerance or general quality-of-life scores across all trials.


Evidence for use following Myocardial Infarction (MI)

Research exploring Carvedilol following a heart attack in patients with reduced heart function is centered on a pivotal, multinational Randomized Controlled Trial. The primary outcomes monitored included survival (all-cause mortality) and the incidence of subsequent non-fatal reinfarction (a second heart attack). Findings describe patterns observed in the studies related to both all-cause mortality and reinfarction frequency in the study group compared to the control group. Limited information is available for the long-acting, extended-release capsule formulation, as the pivotal trial was conducted using the immediate-release tablet.


Evidence for use in High Blood Pressure (Hypertension)

Carvedilol was evaluated in various Randomized Controlled Trials and comparative studies that included other anti-hypertensive agents for patients with essential hypertension. Research explored short-term changes in blood pressure readings and heart rate, along with effects on metabolic markers and kidney function. Comparative studies have reported patterns in metabolic markers that differed from those observed with some older beta-blockers. The certainty remains low regarding the direct, long-term impact on clinical events like stroke or all-cause mortality when Carvedilol is used solely for hypertension.


Research Gaps and Areas of Uncertainty

Long-term effects are not fully established beyond the observation periods of the original RCTs. Subgroup findings are uncertain for certain low-risk populations in the heart failure context. While Carvedilol was observed in trials that included children and adolescents, the findings were mixed regarding clinical outcomes in this specific, younger population.

Frequently Asked Questions (FAQ)

Common questions about Karvedilol (FAQ)


Q: What is the main reason a doctor would prescribe Karvedilol?

A: According to official product information, Karvedilol is indicated for treating a few major heart and circulatory conditions. These include chronic heart failure, left ventricular dysfunction (a type of reduced heart function) that occurs after a heart attack, and essential hypertension (high blood pressure).


Q: How quickly should I expect to feel any difference after starting Karvedilol?

-A: Regulatory information indicates that when starting treatment or increasing a dose, transient symptoms like dizziness or lightheadedness may occur, often felt within the first hour. The full therapeutic effects are associated with the drug's gradual dose adjustment as described in the official guidance.


Q: Are there certain foods or drinks that should be avoided while taking Karvedilol?

A: Official guidance states that the immediate-release tablets are required to be taken with food to modulate how the body absorbs the medicine. Additionally, use with alcohol may increase the risk of low blood pressure effects. It is generally recommended to review consumption of products like grapefruit with a healthcare provider.


Q: Is Karvedilol the kind of drug you have to take forever?

A: Official guidance describes the medication as intended for the long-term management of chronic cardiovascular conditions. Official documents strongly advise that if discontinuation is necessary, the dose must be gradually reduced over one to two weeks, as stopping suddenly can worsen coronary artery disease.


Q: What is the typical timeframe before Karvedilol reaches its full effect?

-A: For managing essential hypertension (high blood pressure), the full antihypertensive effect is typically seen within 7 to 14 days of beginning treatment or reaching a stable dose. The overall time depends on the dose titration process described in the official administration guidelines.


Q: What are the most common reasons why someone might need to stop taking Karvedilol?

A: Official guidance describes that dose reduction or discontinuation may be necessary if a patient experiences persistent or severe side effects. This can include common issues like dizziness and fatigue, or if more serious effects like severe bradycardia (slow heart rate) or significant hypotension (low blood pressure) occur.


Q: How does Karvedilol affect blood sugar levels?

A: Official product information lists hyperglycemia (high blood sugar) as a common adverse reaction. For diabetic patients, the medication can enhance the blood-sugar-reducing effects of other medicines and may mask the typical symptoms of hypoglycemia (low blood sugar), requiring careful monitoring.


Q: What are the differences between the immediate-release and extended-release forms of Karvedilol?

A: The primary difference is the administration schedule. The immediate-release tablet is generally taken twice daily, while the extended-release capsule is taken once daily. The extended-release form is designed to provide a sustained, consistent level of the drug in the body over a full 24-hour period.


Q: Are there any specific safety warnings for people with liver or kidney issues when taking Karvedilol?

A: Official regulatory warnings state that the medicine is contraindicated (must not be used) in people with severe hepatic (liver) impairment. Warnings also address the potential for deterioration of renal (kidney) function, meaning these patients require careful oversight.


Q: Can this drug be taken at any time of day?

A: The medication is prescribed on a specific schedule (once or twice daily). Official guidance specifies that the doses are expected to be taken on a consistent schedule each day, and the immediate-release tablets must always be taken with food.


Q: How is the safety profile of Karvedilol described in official documents?

A: Official documents emphasize that the drug is not intended to be stopped suddenly due to the risk of precipitating acute coronary artery disease. Warnings also highlight potential serious effects such as severe bradycardia, hypotension, and the worsening of heart failure symptoms during dose changes.


Q: Are there official research findings about Karvedilol's long-term effects on kidney function?

A: Pharmacokinetic studies have examined how the body handles the drug in certain populations. These reports indicate that the plasma concentrations of Karvedilol can be increased in hypertensive patients who have moderate to severe renal (kidney) impairment compared to those with normal function.


Q: Can Karvedilol be crushed or split?

A: The extended-release capsules and their contents must not be crushed, chewed, or divided. Specific instructions for crushing or splitting the immediate-release tablets are generally determined by a healthcare professional.


Q: Is it a problem if I occasionally forget to take Karvedilol at the exact same time?

A: The medicine should be taken on a consistent daily schedule. If a dose is missed, official instructions advise omitting the missed dose and taking the next scheduled dose at the regular time, without taking a double dose.


Q: Can Karvedilol affect sleep or cause insomnia?

A: Official regulatory reports indicate that sleep disorders, including insomnia, have been reported as uncommon side effects in patients taking the medicine, typically affecting 0.1% to 1% of participants in clinical trials.


Q: Can this medication interact with over-the-counter pain relievers?

A: Official guidance notes that some over-the-counter medicines, such as non-steroidal anti-inflammatory drugs (NSAIDs), may potentially increase blood pressure. For this reason, it is noted that all non-prescription pain relievers are generally reviewed by a healthcare provider.


Q: Are there any known issues with taking Karvedilol and certain vitamins or supplements?

A: Official guidance warns that complementary medicines, vitamins, and herbal supplements are not systematically tested for interaction with the drug in the same way as prescription medicines. Therefore, the official recommendation is that the use of any supplement be disclosed to a healthcare provider.


Q: Can Karvedilol be used by older adults?

A: Yes, official dosing guidelines provide instructions and considerations for patients in the older adult population (typically defined as those over 65 years of age), confirming its established use in this group.


Q: Is Karvedilol known to cause cold hands or feet?

A: Yes, regulatory documents list disturbances of peripheral circulation, specifically cold extremities (cold hands and feet), as a common side effect, typically affecting between 1% and 10% of patients.


Q: Is Karvedilol primarily used for high blood pressure?

A: The medication is approved for treating three major conditions: chronic heart failure, left ventricular dysfunction after a heart attack, and essential hypertension (high blood pressure). Official documents list all three as valid indications.


Q: Does Karvedilol have any impact on cholesterol levels?

A: Yes, official adverse event data lists having a large amount of cholesterol in the blood (hypercholesterolemia) as a less common side effect reported in clinical trials.


Q: Are there common skin reactions associated with Karvedilol?

A: Official information lists potential skin reactions that may occur. These include red skin lesions and, in rare instances, more serious reactions such as blistering, peeling, or loosening of the skin.


Q: Does Karvedilol interact with caffeine?

A: While there is no major drug interaction listed, official guidance describes that patients experiencing cold hands or feet may consider avoiding drinks with caffeine, as caffeine may worsen this side effect.


Q: Are there any known interactions with herbal supplements like St. John's Wort?

A: Official guidance notes that the drug's metabolism can be affected by certain supplements. The official recommendation is that all herbal supplements, including St. John's Wort, be disclosed to a healthcare provider.


Q: Is Karvedilol a brand name or a generic drug?

A: The drug is available as the generic compound Karvedilol. The medication is also sold under the brand name COREG (or COREG CR for the extended-release form) in many regions.


Q: Is Karvedilol associated with any specific mood changes or depression?

A: Yes, official adverse event reports list depression or a depressed mood as a common side effect, typically affecting between 1% and 10% of patients in clinical trials.


Q: What is the meaning of the half-life of Karvedilol in simple terms?

A: The half-life of a drug is a measure of how quickly the body eliminates it. Karvedilol is reported to have a half-life typically between 7 and 10 hours, which means it takes that amount of time for the concentration of the drug in the body to be reduced by half.

How should Karvedilol be stored and disposed of?

Carvedilol must be stored according to specific regulatory requirements to ensure its stability.


Official Storage and Disposal Instructions

Storage Component Requirement (as per Official Labeling)
Temperature Controlled Room Temperature: 20 C to 25 C (68 F to 77 F)
Protection Protect from both moisture and light.
Container Keep in a tightly closed, light-resistant container.
Child Safety Must be kept out of the sight and reach of children.
Stability Note Extended-release contents mixed with applesauce must be used immediately and not stored.
Disposal Dispose of unused or expired product in accordance with local requirements.

The medication should not be stored in environments like the bathroom. When no longer needed, outdated product should be safely discarded following local pharmaceutical waste protocols.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Karvedilol found in:

A-Z Index: